MedTrace Logo

Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema

NCT01208948 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2010-09-24

No results posted yet for this study

Summary

To evaluate the effect of alpha lipoic acid (ALA) on the occurrence of diabetic macular edema.

Conditions

Interventions

DRUG

1,2 dithiolane 3 valeric acid

600 mg alpha lipoic acid per day

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Michael W Ulbig, MD · Ludwig-Maximilians - University of Munich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2005-04-30
Completion
2005-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208948 on ClinicalTrials.gov